Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells

Gene Therapy

Volumn 7, Issue 9, 2000, Pages 805-812

  Matzner, U ^a   Habetha, M ^a   Gieselmann, V ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Arylsulfatase A; Gene therapy; Lysosomal storage disease; Metachromatic leukodystrophy; Murine stem cell virus

Indexed keywords

CEREBROSIDE SULFATASE; COMPLEMENTARY DNA; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; ENZYME DEFICIENCY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; METABOLIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS;

ANIMALS; CELL LINE; CEREBROSIDE-SULFATASE; GENE THERAPY; GENETIC VECTORS; HUMANS; LEUKODYSTROPHY, METACHROMATIC; MICE; MICE, KNOCKOUT; RETROVIRIDAE;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 85047696614     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301150     Document Type: Article

References (38)

1. Kolodny EH, Fluharty AL. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill: New York, 1995, pp 2693-2740.
2. Hess B et al. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci USA 1996; 93: 14821-14826.
3. Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nature Med 1997; 3: 771-774.
4. Daly TM et al. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA 1999; 96: 2296-2300.
5. Stein CS, Ghodsi A, Derksen T, Davidson BL. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 1999; 73: 3424-3429.
6. Ghodsi A et al. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther 1998; 9: 2331-2340.
7. Cheng L et al. Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood 1998; 92: 83-92.
8. Hawley RG, Lieu FHL, Fong AZC, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
9. Matzner U et al. Long term expression and transfer of arylsulfatase A into brain in arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector (submitted for publication).
10. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 1992; 61: 307-330.
11. Stein C et al. Cloning and expression of human arylsulfatase A. J Biol Chem 1989; 264: 1252-1259.
12. Emmerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1986; 95: 459-467.
13. Sanes JR et al. Lineage, migration, and phenotype in avian optic tectum: analysis with recombinant retroviral vectors. In Gage FH, Christen Y (eds). Gene Transfer and Therapy in the Nervous System. Springer: Berlin, 1992, pp 59-75.
14. Rommerskirch W et al. Restoration of arylsulphatase A activity in human-metachromatic-leucodystrophy fibroblasts via retroviral-vector-mediated gene transfer. Biochem J 1991; 280: 459-461.
15. Ohashi T, Matalon R, Barranger JA, Eto Y. Overexpression of arylsulfatase A gene in fibroblasts from metachromatic leukodystrophy patients does not induce a new phenotype. Gene Therapy 1995; 2: 363-368.
16. Waheed A, Hasilik A, von Figura K. Enhanced breakdown of arylsulfatase A in multiple sulfatase deficiency. J Biochem 1982; 123: 317-321.
17. Varmus H. Retroviruses. Science 1988; 240: 1427-1435.
18. Krall WJ et al. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood 1994; 83: 2737-2748.
19. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 1997; 90: 986-993.
20. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991; 60: 257-280.
21. Hoogerbrugge PM, Valerio D. Bone marrow transplantation and gene therapy for lysosomal storage diseases. Bone Marrow Transplant 1998; 21 (Suppl. 2): 34-36.
22. Walkley SU, Dobrenis K. Bone marrow transplantation for lysosomal diseases. Lancet 1995; 345: 1382-1383.
23. Penzien JM et al. Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease. Am J Genet 1993; 52: 557-564.
24. Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992; 88: 513-523.
25. Learish R et al. Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Therapy 1996; 3: 343-349.
26. Sangalli A et al. Transduced fibroblasts and metachromatic leukodystrophy lymphocytes transfer arylsulfatase A to myelinating glia and deficient cells in vitro. Hum Gene Ther 1998; 9: 2111-2119.
27. Hock RA, Miller AD, Osborne WR. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 1989; 74: 876-881.
28. Plavec I et al. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Therapy 1997; 4: 128-139.
29. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
30. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
31. Aloisi F, Agresti C, Levi GJ. Establishment, characterization, and evolution of cultures enriched in type-2 astrocytes. J Neurosci Res 1988; 21: 188-198.
32. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Plainview, New York, 1989.
33. Preparation of a specific retrovirus producer cell line. In: Ausubel FM et al (eds). Current Protocols in Molecular Biology. John Wiley. Chichester, 1995, unit 9.10.
34. Baum H, Dodgsen KS, Spencer B. The assay of aryl sulfatase A and B in human urine. Clin Chim Acta 1959; 4: 453-455.
35. Levvy GA, Conchie J. Mammalian glycosidases and their inhibition by aldonolactones. Meth Enzymol 1966; 8: 571-584.
36. Sommerlade HJ, Hille-Rehfeld A, von Figura K, Gieselmann V. Four monoclonal antibodies inhibit the recognition of arylsulphatase A by the lysosomal enzyme phosphotransferase. Biochem J 1994; 297: 123-130.
37. Monti E et al. Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts. Biochim Biophys Acta 1992; 1124: 80-87.
38. Schierau A et al. Interaction of arylsulfatase A with UDP-N-acetylglucosamine:lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase. J Biol Chem 1999; 274: 3651-3658.